<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086411</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-15365-1</org_study_id>
    <secondary_id>R01DA015365</secondary_id>
    <nct_id>NCT00086411</nct_id>
  </id_info>
  <brief_title>Comparing Smoking Treatment Programs for Lighter Smokers - 1</brief_title>
  <official_title>Comparing Smoking Treatment Programs for Lighter Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Gariti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare two different types of Food and Drug Administration
      (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in
      conjunction with two levels of counseling. It was hypothesized that the higher level of
      counseling would have the highest rates of treatment completion and highest rates of
      abstinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study compared a minimal level counseling model to a higher level counseling model plus
      one of two types of FDA approved smoking cessation products (bupropion or the nicotine
      patch)used to achieve long term abstinence among lighter smokers. Each participant received
      both products under blinded conditions meaning that neither the participant nor the counselor
      knew which product was real or a placebo. The primary goal was to determine the combination
      or combinations of high or low intensity counseling and pharmacotherapy (either bupropion or
      the nicotine patch) that were most effective for lighter smokers. The main hypothesis was
      that higher level counseling would contribute to improved outcomes meaning that more
      counseling would be associated higher abstinence rates following the completion of treatment
      and at longer term follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Treatment Sessions Attended</measure>
    <time_frame>52 weeks</time_frame>
    <description>Completion of Treatment and Smoking Cessation by Two Different Types of Medications and Counseling Types at 12, 26, and 52 Weeks Post-treatment Initiation. The counseling types were Medication Management (MM) and Mayo counseling models. MM counseling was a 4 session lower intensity counseling model and Mayo counseling was a 10 session higher intensity model.
A twofold definition of treatment completion included both medication and counseling session adherence. Treatment completion was defined as consistently taking the active medication as prescribed (80%) of the time during the medication period and attending at least 7 of the 10 required High C sessions or 3 of the 4 Low C sessions. Participants had to meet both requirements to be designated as full treatment completers.
Seven-day point prevalence abstinence was the primary measure of abstinence at follow-up Weeks 12, 24, and 52. Abstinence was confirmed by biochemical testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delineate Mediators Associated With Different Treatment Conditions (i.e., Medication Compliance, Participant Views of Self-help Written Materials and Counseling Type.</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>1: Bup+MM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bupropion and MM counseling with placebo patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Bup+Mayo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bupropion and Mayo counseling with placebo patch.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Patch+MM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patch and MM counseling with placebo pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Patch+Mayo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patch and Mayo counseling with placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine transdermal system</intervention_name>
    <description>starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.</description>
    <arm_group_label>3 Patch+MM</arm_group_label>
    <arm_group_label>4 Patch+Mayo</arm_group_label>
    <other_name>Nicoderm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion</intervention_name>
    <description>150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks</description>
    <arm_group_label>1: Bup+MM</arm_group_label>
    <arm_group_label>2 Bup+Mayo</arm_group_label>
    <other_name>Zyban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medication Management</intervention_name>
    <description>Brief manual based therapy; four 15 minute session over 10 weeks.</description>
    <arm_group_label>1: Bup+MM</arm_group_label>
    <arm_group_label>3 Patch+MM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mayo Counseling</intervention_name>
    <description>Manual based therapy; Weekly 30 minute sessions for 10 weeks</description>
    <arm_group_label>2 Bup+Mayo</arm_group_label>
    <arm_group_label>4 Patch+Mayo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo patch</intervention_name>
    <description>placebo patch containing no nicotine</description>
    <arm_group_label>1: Bup+MM</arm_group_label>
    <arm_group_label>2 Bup+Mayo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo bupropion</intervention_name>
    <description>placebo pills</description>
    <arm_group_label>3 Patch+MM</arm_group_label>
    <arm_group_label>4 Patch+Mayo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Light smokers (6-15 cigarettes per day

        Inclusion Criteria:

        Mentally and physically stable, non-pregnant, light smokers (6-15 cigarettes per day)

        Exclusion Criteria:

        Please contact site for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter W Gariti, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104 6178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gariti P, Levin S, Whittingham T, Barou D, Kampman KM, Lynch K, Halbert CH, Alterman A. Why do those who request smoking treatment fail to attend the first appointment? J Subst Abuse Treat. 2008 Jul;35(1):62-7. Epub 2007 Oct 10.</citation>
    <PMID>17931823</PMID>
  </reference>
  <results_reference>
    <citation>Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K. Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. J Subst Abuse Treat. 2009 Oct;37(3):247-55. doi: 10.1016/j.jsat.2009.01.006. Epub 2009 Mar 31.</citation>
    <PMID>19339135</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2004</study_first_submitted>
  <study_first_submitted_qc>July 6, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2004</study_first_posted>
  <results_first_submitted>June 24, 2013</results_first_submitted>
  <results_first_submitted_qc>January 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2014</results_first_posted>
  <last_update_submitted>January 24, 2014</last_update_submitted>
  <last_update_submitted_qc>January 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Peter Gariti</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>light smokers, smoking cessation treatment programs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The sample consists of 260 self-referred lighter smokers to an urban university setting. The first participant was enrolled in February 2005, and the last follow-up was completed in March 2008. A total of 302 met confirmatory screening criteria, and 260 were enrolled.</recruitment_details>
      <pre_assignment_details>An in-person confirmatory screening interview consisted of a medical examination, structured psychological interview (Mini International Neuropsychiatric Interview; Sheenan et al., 1997), and biochemical testing (i.e., carbon monoxide reading of expired air [CO], blood alcohol concentration,and urine drug test).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Bup+MM</title>
          <description>bupropion and MM with placebo patch</description>
        </group>
        <group group_id="P2">
          <title>2 Bup+Mayo</title>
          <description>bupropion and Mayo counseling with placebo patch.</description>
        </group>
        <group group_id="P3">
          <title>3 Patch+MM</title>
          <description>patch and MM with placebo pills</description>
        </group>
        <group group_id="P4">
          <title>4 Patch+Mayo</title>
          <description>patch and Mayo counseling with placebo patch</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="62"/>
                <participants group_id="P4" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1: Bup+MM</title>
          <description>bupropion and MM with placebo patch</description>
        </group>
        <group group_id="B2">
          <title>2 Bup+Mayo</title>
          <description>bupropion and Mayo counseling with placebo patch.</description>
        </group>
        <group group_id="B3">
          <title>3 Patch+MM</title>
          <description>patch and MM with placebo pills</description>
        </group>
        <group group_id="B4">
          <title>4 Patch+Mayo</title>
          <description>patch and Mayo counseling with placebo patch</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="62"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="260"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="12.5"/>
                    <measurement group_id="B2" value="42.4" spread="12.6"/>
                    <measurement group_id="B3" value="45.8" spread="12.6"/>
                    <measurement group_id="B4" value="43.1" spread="11.3"/>
                    <measurement group_id="B5" value="43.3" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Treatment Sessions Attended</title>
        <description>Completion of Treatment and Smoking Cessation by Two Different Types of Medications and Counseling Types at 12, 26, and 52 Weeks Post-treatment Initiation. The counseling types were Medication Management (MM) and Mayo counseling models. MM counseling was a 4 session lower intensity counseling model and Mayo counseling was a 10 session higher intensity model.
A twofold definition of treatment completion included both medication and counseling session adherence. Treatment completion was defined as consistently taking the active medication as prescribed (80%) of the time during the medication period and attending at least 7 of the 10 required High C sessions or 3 of the 4 Low C sessions. Participants had to meet both requirements to be designated as full treatment completers.
Seven-day point prevalence abstinence was the primary measure of abstinence at follow-up Weeks 12, 24, and 52. Abstinence was confirmed by biochemical testing.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1: Bup+MM</title>
            <description>bupropion and MM with placebo patch</description>
          </group>
          <group group_id="O2">
            <title>2 Bup+Mayo</title>
            <description>bupropion and Mayo counseling with placebo patch.</description>
          </group>
          <group group_id="O3">
            <title>3 Patch+mm</title>
            <description>patch and MM with placebo pills</description>
          </group>
          <group group_id="O4">
            <title>4 Patch+Mayo</title>
            <description>patch and Mayo counseling with placebo patch</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Treatment Sessions Attended</title>
          <description>Completion of Treatment and Smoking Cessation by Two Different Types of Medications and Counseling Types at 12, 26, and 52 Weeks Post-treatment Initiation. The counseling types were Medication Management (MM) and Mayo counseling models. MM counseling was a 4 session lower intensity counseling model and Mayo counseling was a 10 session higher intensity model.
A twofold definition of treatment completion included both medication and counseling session adherence. Treatment completion was defined as consistently taking the active medication as prescribed (80%) of the time during the medication period and attending at least 7 of the 10 required High C sessions or 3 of the 4 Low C sessions. Participants had to meet both requirements to be designated as full treatment completers.
Seven-day point prevalence abstinence was the primary measure of abstinence at follow-up Weeks 12, 24, and 52. Abstinence was confirmed by biochemical testing.</description>
          <units>Percentage of attended tx. sessions</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" spread=".05"/>
                    <measurement group_id="O2" value="85.9" spread=".04"/>
                    <measurement group_id="O3" value="66.8" spread=".06"/>
                    <measurement group_id="O4" value="66.6" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Rates of abstinence were addressed using a generalized estimating equations (GEE) logistic regression model. Counseling type and medication type were entered as the main explanatory variables along with time and the interaction of these factors, together with some covariates (described below). The sample size provided 80% power to detect a difference of about 14% between groups across three time points (i.e., 12, 26, and 52 weeks post-treatment initiation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.017</p_value>
            <p_value_desc>The p-value was adjusted for multiple comparisons.</p_value_desc>
            <method>GEE model for repeated binary outcomes</method>
            <method_desc>Model included hx of heavy smoking, elevated depression, cigarettes per day, gender, and race</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2734</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>2.25</ci_upper_limit>
            <estimate_desc>The above was for the main effect of BUP versus NTX on cessation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delineate Mediators Associated With Different Treatment Conditions (i.e., Medication Compliance, Participant Views of Self-help Written Materials and Counseling Type.</title>
        <time_frame>52 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The reported time frame for study related serious adverse events was 1 year. Two participants died prior to the week 52 follow-up of non-study related problems. The reported time frame for adverse events is the first 12 weeks (3 weeks post medication).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1: Bup+MM</title>
          <description>bupropion and MM with placebo patch</description>
        </group>
        <group group_id="E2">
          <title>2 Bup+Mayo</title>
          <description>bupropion and Mayo counseling with placebo patch.</description>
        </group>
        <group group_id="E3">
          <title>3 Patch+mm</title>
          <description>patch and MM with placebo pills</description>
        </group>
        <group group_id="E4">
          <title>4 Patch+Mayo</title>
          <description>patch and Mayo counseling with placebo patch</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medication stopped due to reported side effects.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Missing data from some early terminations from treatment (i.e., 2 or less visits) may reflect dissatisfaction with counseling assignment or medication effects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Gariti, Ph.D.</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-222-3200 ext 0</phone>
      <email>gar1iti@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

